JP2024150674A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024150674A5 JP2024150674A5 JP2024119250A JP2024119250A JP2024150674A5 JP 2024150674 A5 JP2024150674 A5 JP 2024150674A5 JP 2024119250 A JP2024119250 A JP 2024119250A JP 2024119250 A JP2024119250 A JP 2024119250A JP 2024150674 A5 JP2024150674 A5 JP 2024150674A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- variable region
- seq
- acid sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721505P | 2018-08-22 | 2018-08-22 | |
| US62/721,505 | 2018-08-22 | ||
| PCT/US2019/047728 WO2020041604A1 (en) | 2018-08-22 | 2019-08-22 | Anti-her2 polypeptides and methods of use thereof |
| JP2021510094A JP2021534220A (ja) | 2018-08-22 | 2019-08-22 | 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510094A Division JP2021534220A (ja) | 2018-08-22 | 2019-08-22 | 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024150674A JP2024150674A (ja) | 2024-10-23 |
| JP2024150674A5 true JP2024150674A5 (https=) | 2025-04-11 |
| JP7818042B2 JP7818042B2 (ja) | 2026-02-19 |
Family
ID=67989062
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510094A Pending JP2021534220A (ja) | 2018-08-22 | 2019-08-22 | 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法 |
| JP2024119250A Active JP7818042B2 (ja) | 2018-08-22 | 2024-07-25 | 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510094A Pending JP2021534220A (ja) | 2018-08-22 | 2019-08-22 | 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220002436A1 (https=) |
| EP (1) | EP3840781A1 (https=) |
| JP (2) | JP2021534220A (https=) |
| KR (1) | KR20210074279A (https=) |
| CN (1) | CN113286610A (https=) |
| AR (1) | AR115998A1 (https=) |
| AU (2) | AU2019326545A1 (https=) |
| BR (1) | BR112021002953A2 (https=) |
| CA (1) | CA3141815A1 (https=) |
| EA (1) | EA202190603A1 (https=) |
| IL (2) | IL326298A (https=) |
| MX (1) | MX2021001976A (https=) |
| SG (1) | SG11202101436SA (https=) |
| TW (1) | TW202017947A (https=) |
| WO (1) | WO2020041604A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| PH12022551598A1 (en) | 2019-12-23 | 2023-11-20 | Denali Therapeutics Inc | Progranulin variants |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| AU2021224200A1 (en) * | 2020-02-19 | 2022-09-08 | Denali Therapeutics Inc. | Engineered anti-HER2 bispecific proteins |
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| WO2023038803A2 (en) * | 2021-08-25 | 2023-03-16 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| WO2023128702A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 아임뉴런 | 뇌혈관장벽 투과성 융합 단백질 및 이의 용도 |
| KR20240067001A (ko) * | 2022-10-28 | 2024-05-16 | 주식회사 아임뉴런 | 뇌혈관장벽 투과성 융합 단백질 및 이의 용도 |
| EP4631975A1 (en) * | 2022-12-08 | 2025-10-15 | Adel Inc. | Fusion comprising anti-tau antibody and peptide and use thereof |
| CN120648654A (zh) * | 2024-03-13 | 2025-09-16 | 深圳太力生物技术有限责任公司 | 重组细胞的制备方法、重组细胞及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1699826B1 (en) * | 2005-01-05 | 2009-03-11 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| HUE045144T2 (hu) * | 2012-08-29 | 2019-12-30 | Hoffmann La Roche | Véragygát-shuttle |
| WO2014089209A2 (en) * | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| WO2015191934A2 (en) * | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
| CN107531788B (zh) * | 2015-06-24 | 2022-06-21 | 豪夫迈·罗氏有限公司 | 对her2和血脑屏障受体特异性的三特异性抗体及使用方法 |
| CN107446045A (zh) * | 2016-07-22 | 2017-12-08 | 北京天广实生物技术股份有限公司 | 一种抗her2的抗体、其药物组合物及用途 |
| CN110506055A (zh) * | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| SG11201907422RA (en) * | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| EP3665194A4 (en) * | 2017-08-10 | 2021-07-07 | Denali Therapeutics Inc. | AFFINITY BASED METHODS OF USING TRANSFERRIN RECEPTOR BINDING PROTEINS |
-
2019
- 2019-08-22 JP JP2021510094A patent/JP2021534220A/ja active Pending
- 2019-08-22 CN CN201980068845.5A patent/CN113286610A/zh active Pending
- 2019-08-22 WO PCT/US2019/047728 patent/WO2020041604A1/en not_active Ceased
- 2019-08-22 IL IL326298A patent/IL326298A/en unknown
- 2019-08-22 MX MX2021001976A patent/MX2021001976A/es unknown
- 2019-08-22 SG SG11202101436SA patent/SG11202101436SA/en unknown
- 2019-08-22 EA EA202190603A patent/EA202190603A1/ru unknown
- 2019-08-22 TW TW108130121A patent/TW202017947A/zh unknown
- 2019-08-22 AU AU2019326545A patent/AU2019326545A1/en not_active Abandoned
- 2019-08-22 EP EP19769934.1A patent/EP3840781A1/en active Pending
- 2019-08-22 BR BR112021002953-2A patent/BR112021002953A2/pt unknown
- 2019-08-22 AR ARP190102390A patent/AR115998A1/es unknown
- 2019-08-22 CA CA3141815A patent/CA3141815A1/en active Pending
- 2019-08-22 KR KR1020217008163A patent/KR20210074279A/ko not_active Ceased
-
2021
- 2021-02-16 IL IL280922A patent/IL280922B1/en unknown
- 2021-02-18 US US17/178,595 patent/US20220002436A1/en active Pending
-
2024
- 2024-07-25 JP JP2024119250A patent/JP7818042B2/ja active Active
-
2026
- 2026-01-07 AU AU2026200081A patent/AU2026200081A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024150674A5 (https=) | ||
| JP2021510162A5 (https=) | ||
| JP2021534220A5 (https=) | ||
| US11325982B2 (en) | Biparatopic and multiparatopic antibodies with common light chain and method of use | |
| JP2020196744A5 (https=) | ||
| US9505848B2 (en) | Engineered heterodimeric protein domains | |
| JP2021533779A5 (https=) | ||
| CN102369214B (zh) | 三价、双特异性抗体 | |
| JP2022551969A5 (https=) | ||
| RU2015145719A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| CN106164095A (zh) | 多特异性抗体 | |
| JP2021521781A5 (https=) | ||
| US20220119549A1 (en) | Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof | |
| AU2018387829B2 (en) | Bispecific antigen binding construct | |
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JPWO2022102768A5 (https=) | ||
| AU2021224787A1 (en) | CD137 binding molecules and uses thereof | |
| IL318098A (en) | IGE-FCER pushers | |
| CN119546637A (zh) | 与FCγ受体的结合降低的嵌合重链恒定结构域及其用途 | |
| US12486321B2 (en) | Agents that interfere with IL-1BETA receptor signalling | |
| US20260055171A1 (en) | Vegf antagonists and methods of use thereof | |
| US20240287162A1 (en) | Multivalent anti-spike protein binding molecules and uses thereof | |
| US20240309072A1 (en) | Multivalent anti-spike protein binding molecules and uses thereof | |
| JP2025511000A5 (https=) | ||
| CA3229542A1 (en) | Anti-her2 antibodies and methods of use thereof |